Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2020-04-16 Capital/Financing Update
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC by Aeglea BioTherapeutics, Inc. It reports on the entry into a material definitive agreement related to a capital raising sales agreement, termination of a prior agreement, and provides a business update including clinical trial information. The document is a current report on material events and agreements, not a full annual or quarterly financial report. It contains detailed disclosures about financing arrangements and business developments but does not present comprehensive financial statements or detailed financial analysis. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains substantive information about financing activities and business updates, consistent with CAP filings.
2020-04-16 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and base prospectus related to a securities offering, specifically a common stock offering under a sales agreement. It includes detailed information about the offering, risk factors, use of proceeds, plan of distribution, and legal matters. The document is filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, which is a regulatory filing related to securities offerings. It is not a financial report, earnings release, management discussion, or any other type of report but rather a capital raising document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full prospectus supplement, not just an announcement of a report, confirming it is a substantive filing about financing.
2020-04-16 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Aeglea BioTherapeutics, Inc. dated April 8, 2020. It reports on "Other Events" specifically the approval of a Clinical Trial Application and updates on clinical trials impacted by the COVID-19 pandemic. The document includes detailed risk factors related to COVID-19 and its impact on the company's business and clinical trials. It is not a full annual or quarterly report, nor an earnings release or management discussion. It is a regulatory filing to disclose material events outside of regular periodic reports. The document is about 13,475 characters, which is substantial but typical for an 8-K. The content fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release, capital update, or management report. Therefore, the correct classification is Regulatory Filings (RNS).
2020-04-08 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 31, 2020. It announces an amendment and restatement of the company's bylaws, specifically adopting a provision about exclusive jurisdiction for litigation. The document includes a description of the bylaw changes and references the full text of the amended bylaws filed as an exhibit. There are no financial statements or detailed financial data presented. The document is a regulatory announcement about governance changes, specifically amendments to the bylaws, which falls under Board/Management Information (MANG) as it relates to changes in company governance documents. The document length is 3558 characters, which is relatively short and consistent with an 8-K announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2020-04-03 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Aeglea BioTherapeutics, Inc. It registers additional shares of common stock under the company's 2016 Equity Incentive Plan and 2016 Employee Stock Purchase Plan. The document includes details about the registration fee, incorporation by reference of prior filings, and signatures of company officers. Form S-8 is a registration statement used for securities to be offered under employee benefit plans, which is a type of capital raising related to employee stock plans. This fits the category of Capital/Financing Update (CAP) as it relates to registration of securities for issuance under employee plans, not a financial report or other filing type. The document length is over 12,000 characters and contains substantive information about the registration, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2020-02-24 English
10-K
Annual Report FY 2019
2020-02-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.